Chapter 8

Valuation and Scenarios

At $141.61 the market values Gartner's equity near $10.0 billion — about 10 times forward earnings and an 11-12% free-cash-flow yield. Reverse-engineered, that price discounts free cash flow shrinking roughly 3% a year in perpetuity. That is terminal-decline pricing for a franchise whose cash flow is broadly flat and whose contract base still grew 1% last year. The 74% drawdown re-rated a belief about durability, not the cash the business currently produces.

What the market pays today

Sources: 70,450,294 shares outstanding, FY2025 Form 10-K cover [1]; net debt from cash $1,722.5M and total debt $2,981.7M, Consolidated Balance Sheet [2]; FY2025 adjusted EBITDA $1,611M, 4Q25 earnings supplement reconciliation [3]; price and consensus per market data as of July 7, 2026.

The building blocks are simple. Roughly 70.5 million shares at $141.61 put equity value near $10.0 billion [4]. Net debt of $1.26 billion — total debt of $2,981.7 million less $1,722.5 million of cash — lifts enterprise value to about $11.2 billion [5]. Against FY2025 free cash flow of $1,175 million and adjusted EBITDA of $1,611 million, that is 9.6 times free cash flow, 7.0 times EBITDA, and — on consensus FY2026 earnings — a little over 10 times.

Sources: GAAP EPS $9.65 and FCF ($1,290.4M operating cash flow less $115.1M capex), FY2025 Form 10-K [6]; FY2026 guidance (adj. EPS $12.30, FCF $1,135M) 4Q25 earnings supplement [7]; consensus EPS per estimates as of July 2026. Multiples derived.

None of these numbers is expensive for a business earning a mid-20s return on capital. But cheap and expensive are statements about expectations, so the useful question is what expectation the price encodes.

The cash the franchise produces

Free cash flow is the right lens here: Gartner is capital-light, converts subscription billings to cash ahead of revenue, and returns everything through buybacks. Over five years operating cash flow has held between $0.9 billion and $1.5 billion, and free cash flow between roughly $1.0 billion and $1.4 billion, with capital expenditure never above 2% of revenue [8].

Sources: operating cash flow and capital expenditure, FY2025 and FY2023 Forms 10-K [9]; FY2026 free cash flow is company guidance [10]. FY2026 operating-cash-flow bar shown equal to guided free cash flow for scale.

The honest counterweight sits in that last bar. Management's own 2026 guidance is a step down, not up: adjusted EPS of $12.30 against $13.17 delivered in FY2025, adjusted EBITDA of at least $1,515 million against $1,611 million, and free cash flow of about $1,135 million on roughly 71 million shares [11]. The FY2025 figures it steps down from — $13.17 of adjusted EPS, itself down 6.5% on 2024 — are in the supplement's own history [12]. Two things temper that. Gartner guides to floors — every line carries an "at least" — and has a long record of beating them; consensus already models FY2026 EPS near $13.70, above the guide. And the multi-year framework management still publishes points higher: Insights revenue growth of 12-16%, total revenue growth of at least 10%, with EBITDA, EPS, and free cash flow each set to grow at least as fast [13]. The gap between a flat 2026 and that framework is the whole debate.

What the price implies

Treat free cash flow as the cash available to equity — it already absorbs the roughly $100 million of annual cash interest — and value it as a growing perpetuity. At $141.61, equity value divided by free cash flow gives a cash-flow yield of about 11.8%, which in a single-stage model equals the discount rate minus the perpetual growth rate. Rearranged, the market's embedded growth assumption falls straight out.

Source: derived from FY2025 free cash flow $1,175M and equity value $9,976M; single-stage Gordon model.

Across any reasonable discount rate — 8% to 10% for a stable, investment-grade compounder — the price implies free cash flow declining between roughly 2% and 4% every year, forever. For a business that has never had a down free-cash-flow decade, whose contract value still rose 1% in 2025 against a US federal headwind, and which guides its franchise to double-digit ambitions, that is a demanding thing to assume [14].

The mirror image is what the range is worth under other assumptions. Holding free cash flow near $1,150 million and about 70 million shares, the per-share value swings widely on the two inputs it is most sensitive to — the discount rate and, far more, the terminal growth rate.

Source: derived — single-stage Gordon model on free cash flow of $1,150M and 70M shares; base free cash flow is the midpoint of FY2025 actual ($1,175M) and FY2026 guidance ($1,135M).

The current price sits in the bottom-left of that grid, where free cash flow is assumed to erode. If instead free cash flow merely holds flat, the same model returns $164-$205; if it grows a modest 3%, $242-$338. The independent read from sell-side targets lands in the flat-to-slight-growth band: a mean target of $165 and median of $164, with a range of $120 to $203 across fifteen analysts whose ratings net to a hold. The point is not that any single cell is correct — it is that today's price already prices the bear terminal case, so the burden on a buyer is only to disbelieve permanent decline, not to underwrite growth.

The drawdown against the cash flows

The through-line's open question is whether a share price down about 74% has overstated the damage to the value of Gartner's cash flow. The arithmetic of the drawdown makes the answer concrete.

Sources: peak close $551.80 (Nov 13, 2024) and current price per market data; FCF per FY2025 Form 10-K [15]; embedded growth derived at a 9% discount rate.

At the November 2024 peak of $551.80, equity value was roughly $43 billion against about $1.38 billion of free cash flow — a 3.2% yield that, at a 9% discount rate, embedded nearly 6% perpetual free-cash-flow growth. Today the same discount rate embeds about negative 3%. The cash flows themselves moved by low single digits over that span; the embedded terminal-growth assumption swung roughly nine percentage points, from healthy growth to permanent decline. The re-rating is almost entirely a change in belief about how durable the franchise is, not a change in the cash the franchise generates.

So the selloff does overstate the damage to the cash flow that exists today — but it is a rational price if a buyer believes AI is the leading edge of structural erosion rather than a cyclical soft patch. The valuation question does not stand on its own; it depends on the durability question the report has worked through in Retention and AI. What keeps the bear case live is that the softening is real and recent, not hypothetical: contract value growth has decelerated to 1%, wallet retention rolled below 100% in 2025, and 2026 guidance itself steps down [16]. If those are the first innings of substitution, terminal decline is a forecast, not pessimism.

Three paths

Source: derived — Gordon-model outputs cross-checked to EV/EBITDA multiples; free-cash-flow paths keyed to the contract-value trajectory disclosed in the FY2025 Form 10-K [17].

What separates the paths is one observable series: contract value growth. It is disclosed every quarter, it led the 2025 wallet-retention roll-over, and it is the cleanest early read on whether AI is compounding or eroding the base. A return toward mid-single-digit contract-value growth, with wallet retention back above 100%, would move the read to the base case or better; a second year of deceleration would validate the bear. The watch item is falsifiable and dated.

A ten-year revenue floor

A patient owner's real question is narrower than the multiple: can revenue be higher in ten years than the roughly $6.5 billion earned today? The structural case for yes is strong. About three-quarters of revenue is subscription Insights sold on non-cancelable twelve-month minimums, 77% of it multi-year, with client retention stable in the mid-80s and a deferred-revenue float that pre-funds the year [18]. For revenue to be lower a decade out, contract value would have to decline persistently — which it has not done even through the federal cuts and the AI scare, where it still grew 1% [19].

The calibrated answer is that higher revenue in year ten is clearly more likely than not, but 90% confidence is not warranted. The cautionary case is Forrester, the only same-model pure-play, whose contract value fell and whose revenue shrank about 20% over 2021-2025 once its subscription base cracked — a reminder that this model can go into reverse. Gartner enters the AI decade from a stronger position, with contract value still growing rather than contracting, so the central case is a modestly larger revenue base; the tail is a genuine, sustained substitution that the next several years of contract-value prints will reveal well before year ten.

Expressing the view

For an investor sizing how to hold this, the equity is deeply liquid — an S&P 500 constituent trading roughly $200 million a day, so even a 1% position clears in a handful of sessions. The obstacle to option-based expression is price, not access: 30-day realized volatility runs near 54%, with an average daily range close to 5%, elevated by the drawdown and the AI overhang. At that level, long-dated at-the-money implied volatility is likely in the 40s-to-50s, which makes both protective puts and outright call premium expensive relative to owning the shares. The corpus does not carry a live options chain, so precise implied volatility, open interest, and longest-dated strikes for the January 2027-2028 series should be taken from a real-time quote before acting; the direction — that convexity here is costly and the cleaner expression is the equity itself — is what the volatility data supports.

Source: 30-day realized volatility and average daily range derived from the daily price history through July 7, 2026; options-chain data not present in the corpus.

The evidence points to a price that already discounts permanent decline in a franchise whose cash flow is, so far, merely flat — so the asymmetry favors the owner who can wait for the contract-value series to settle the durability question. The main risk to that read is that 2026's step-down is the start of the erosion the price assumes, not a pause; the quarterly contract-value print is where that gets decided.